Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Evoke Pharma (EVOK) Reports Q2 Loss of $0.93/sh
August 13, 2024 8:15 AM EDTEvoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.93), versus ($6.71) reported last year. Revenue for the quarter came in at $2.55 million, versus $1.13 million reported last year.
Based on net sales generated in the first two quarters of 2024, Evoke is revising its 2024 guidance... More